COMPANY PROFILE

Hervolution Therapeutics

Explore full profile

Immunotherapies targeting dark genome HERV antigens.

Copenhagen, DenmarkFounded 2011Biotech & Life Sciences

Valuation $25–50M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Hervolution Therapeutics

Operator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome. The company offers broad and curative cancer therapy in combination with immune checkpoint inhibitors, enabling medical researchers to easily find treatment for cancer using adaptive immune therapy.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Copenhagen, Denmark
Employees: 35
Open positions: None listed
Dealroom signal: 84.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, EIC, Biotech and Pharma, EIC Fund, Nordic Rising Star 2022, Horizon Europe, DT and LS
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2024	$12M	$47M	Serum Institute of India · EIC Fund	↗
SEED✓Equity / VC	May 2023	$6.6M	$26M	EIC Fund	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Profit	Margin	R&D
2026		—
2025		—
2024		—
2023		—
2022		—
2021		—
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Hervolution Therapeutics website traffic

Latest recorded traffic for Hervolution Therapeutics is 290 monthly website visits, down 27.5% over the last three months. Hervolution Therapeutics's team grew 25% over the past year.

Latest monthly visits290 3-month web change-27.5% 1-year team growth+25%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational	22	$29M	$88M
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational
NPNETRIS PharmaMonoclonal antibodies overcoming cancer therapy resistance.	Lyon, France	Operational
OPOphiomicsOphiomics develops bioinformatics/genomics-based diagnostic products and services for liver cancer diagnosis, prognosis and follow-up.	Lisbon, Portugal	Operational